Notice of allowance of United States Family 3 Breast Cancer patent
DiaGenic has now received notice of allowance of the United States family 3 patent application (11/628,300). The claims allowed cover the use of some important gene sequences or the related proteins in blood sample for detection and monitoring of breast cancer in the US. The patent will be valid until 2025.
The family 3 patent has earlier been granted in Europe and some other countries.
“This patent is the first from DiaGenic that addresses diagnostic tests using either gene expression or protein-based technologies. A broad range of gene probes and related protein targets are included based on DiaGenic’s research within the breast cancer field” said DiaGenic CEO Erik Christensen MD PhD, “It is also the first breast cancer patent to be awarded to DiaGenic in the US and substantially strengthens our portfolio offering to potential US partners”.
Contact:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com